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Abstract
Introduction: Low-intensity pulsed ultrasound (LIPUS) has been known to promote bone healing by nonthermal
effects. In recent studies, LIPUS has been shown to reduce inflammation in injured soft tissues. Xerostomia is one
of the most common symptoms in Sjögren syndrome (SS). It is caused by a decrease in the quantity or quality of
saliva. The successful treatment of xerostomia is still difficult to achieve and often unsatisfactory. The aim of this
study is to clarify the therapeutic effects of LIPUS on xerostomia in SS.
Methods: Human salivary gland acinar (NS-SV-AC) and ductal (NS-SV-DC) cells were cultured with or without tumor
necrosis factor-α (TNF-α; 10 ng/ml) before LIPUS or sham exposure. The pulsed ultrasound signal was transmitted at a
frequency of 1.5 MHz or 3 MHz with a spatial average intensity of 30 mW/cm2 and a pulse rate of 20 %. Cell number,
net fluid secretion rate, and expression of aquaporin 5 (AQP5) and TNF-α were subsequently analyzed. Inhibitory effects
of LIPUS on the nuclear factor κB (NF-κB) pathway were determined by Western blot analysis. The effectiveness of
LIPUS in recovering salivary secretion was also examined in a MRL/MpJ/lpr/lpr (MRL/lpr) mouse model of SS with
autoimmune sialadenitis.
Results: TNF-α stimulation of NS-SV-AC and NS-SV-DC cells resulted in a significant decrease in cell number and net
fluid secretion rate (p < 0.01), whereas LIPUS treatment abolished them (p < 0.05). The expression changes of AQP5
and TNF-α were also inhibited in LIPUS treatment by blocking the NF-κB pathway. Furthermore, we found that
mRNA expression of A20, a negative feedback regulator, was significantly increased by LIPUS treatment after TNF-α or
interleukin 1β stimulation (NS-SV-AC, p < 0.01; NS-SV-DC, p < 0.05). In vivo LIPUS exposure to MRL/lpr mice exhibited a
significant increase in both salivary flow and AQP5 expression by reducing inflammation in salivary glands (p < 0.01).
Conclusions: These results suggest that LIPUS upregulates expression of AQP5 and inhibits TNF-α production. Thus,
LIPUS may restore secretion by inflamed salivary glands. It may synergistically activate negative feedback of NF-κB
signaling in response to inflammatory stimulation. Collectively, LIPUS might be a new strategic therapy for xerostomia
in autoimmune sialadenitis with SS.
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Introduction
Sjögren syndrome (SS) is one of the most common
chronic autoimmune diseases. It is characterized by
lymphocytic infiltrates and destruction of salivary and
lacrimal glands [1, 2]. Patients with SS manifest pro-
gressive dryness of the mouth and eyes due to insuf-
ficient salivary and lacrimal secretions [3].
Currently, the cause of dry mouth (xerostomia) experi-
enced by patients with SS remains unknown. However,
dynamic expression of various cytokines has been de-
tected in the salivary glands of humans, as well as in ex-
perimental animals, during the development of SS [4, 5].
In particular, expression of tumor necrosis factor (TNF)-α
has been strongly associated with decreased salivary flow
in patients with SS [6]. It is indicated that TNF-α inhibits
salivary secretion due to its neurotoxic effect on sympa-
thetic nerves. Aquaporin 5 (AQP5), a water channel pro-
tein, facilitates the rapid transcellular movement of water
in response to osmotic and/or hydrostatic pressure gradi-
ents [7]. On the basis of its reduced expression and abnor-
mal distribution in the salivary and lacrimal glands of
patients with SS, a potential role of AQP5 is proposed.
The treatment of SS remains a challenge because most
of the randomized controlled trials done to date have
failed to demonstrate efficacy of the treatments evaluated.
Hydroxychloroquine (HCQ), one of the most frequently
proposed treatments for SS, is currently used on the basis
of data obtained from an observational study [8] and a
crossover study [9]. However, in a more recent ran-
domized controlled study, the primary endpoint was
not achieved [10]. In a recent clinical report regarding
the chimeric anti-TNF-α antibody infliximab, patients
with SS were found to exhibit a dramatic improvement
in salivary flow [11], though there have been a few
scattered reports of anti-TNF-α treatment inefficacy
[12, 13]. Furthermore, Yamamura et al. [3] found that
TNF-α stimulation dramatically decreased water flow
rate (e.g., salivary flow) in cultured acinar cells of human
salivary glands, supporting the effectiveness of infliximab.
Thus, accumulating evidence suggests that anticytokine
therapy that includes targeted inhibition of TNF-α activity
may represent a treatment for xerostomia caused by auto-
immune sialadenitis in SS. However, a significant number
of patients taking HCQ may be at an increased risk for
retinal toxicity [14], and anti-TNF-α treatment has many
side effects, including anaphylaxis [15], and increased risk
for infections, such as tuberculosis and demyelination,
aplastic anemia, intestinal perforation, lymphoma, and
congestive heart failure [16]. In other words, the estab-
lishment of a treatment with a better side effect profile
is urgently needed.
Low-intensity pulsed ultrasound (LIPUS) has been used
extensively as a therapeutic, operative, and diagnostic tool
in medicine. Previous studies have demonstrated that
LIPUS can promote bone repair and regeneration, acceler-
ate bone fracture healing [17, 18], and enhance osteogen-
esis at the distraction site [19, 20]. Therefore, LIPUS is
well-accepted as a noninvasive and safe therapeutic tool
for the treatment of bone fractures [21].
Recently, the effect of ultrasound on soft tissues has
received much attention. It has been reported that LIPUS
promotes cell proliferation and the synthesis of extracellu-
lar matrix in fibroblasts and myoblasts [22–24]. Further-
more, ultrasound has been shown to reduce inflammation
and promote regeneration in various injured soft tissues
[23, 25, 26]. Thus, ultrasound therapy may have consider-
able clinical potential for shortening the healing time
of injured or pathological soft tissues. However, little
information is available regarding the effect of LIPUS
on salivary glands and the acinar and ductal cells that
compose them. Accordingly, the aim of this study was to
examine the inhibitory effects of LIPUS on cell prolifer-
ation, net fluid secretion rate, and AQP5 expression of
TNF-α-stimulated normal human salivary gland acinar
and ductal cells in vitro. In addition, we analyzed the effect
of LIPUS on the nuclear factor κB (NF-κB) signaling path-
way in the acinar and ductal cells stimulated with TNF-α.
We also evaluated improvement of the effects of LIPUS
on xerostomia in a mouse model of SS.
Methods
Cell culture
Immortalized clones of human salivary gland acinar
(NS-SV-AC) and ductal (NS-SV-DC) cells have been
generated [27]. These cells were cultured at 37 °C in
serum-free keratinocyte medium (SFKM; Gibco/Thermo
Fisher Scientific, Grand Island, NY, USA) in an atmosphere
containing 5 % CO2.
Animals
A total of 10 C57BL/6 and 20 MRL/MpJ/lpr/lpr (MRL/lpr)
female mice were purchased from Japan SLC (Hamamatsu,
Japan) and were used as the control and experimental
groups, respectively. Mice were kept at a constant ambient
temperature (22–24 °C) with a 12-h/12-h light/dark cycle
and received a solid diet ad libitum in the animal facility of
Tokushima University under specific pathogen-free condi-
tions. The experimental protocol described below was
approved by the ethics committee of Tokushima University
(permit number 13015). The control groups included
6-week-old, 12-week-old, 20-week-old, and 24-week-old
mice (n = 5 for each). The experimental groups included
12-week-old and 20-week-old mice (n = 5 for each).
LIPUS
LIPUS was applied by a modified version of the ST-Sonic
clinical device (ITO Co., Tokyo, Japan). The modified
system consisted of a 5.0-cm2 circular surface transducer
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and a cell culture plate. The ultrasound head had a mean
beam nonuniformity value of 2.7 and an effective radiating
area of 4.1 cm2. An ultrasound signal was transmitted at a
frequency of 3 MHz in vitro and 1.5 MHz in vivo. It had a
spatial average intensity value of 30 mW/cm2 and a pulse
rate of 1:4 (2 ms on and 8 ms off). A six-well plate was
maintained in vitro with its top above water level in a
foam-fronted plastic sliding assembly containing an aper-
ture of dimensions matching to the monolayer (Additional
file 1: Figure S1). The distance between the transducer
and the cells was approximately 1 mm. The cell cultures
were treated with 20 min of a single ultrasound ex-
posure. The tank water was maintained at 37 ± 0.5 °C.
The LIPUS exposure assembly was maintained in a
humidified atmosphere of 5 % CO2 at 37 °C during all
experiments, and an electronic control panel activated an
alert signal if the coupling gel or liquid was depleted. Con-
trol samples were treated in parallel, although LIPUS was
not applied. The in vivo submandibular glands of the mice
received 20 min of LIPUS per day for 14 days.
Cell proliferation
Cells were grown in 96-well microplates (2 × 104 cells/
well) in SFKM. After the appropriate incubation period,
the number of attached cells was counted using a Z1
COULTER COUNTER (Beckman Coulter, Fullerton, CA,
USA). Moreover, the 2-(2-meth-oxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium mono-
sodium salt assay was performed using Cell Count
Reagent SF (Nacalai Tesque, Kyoto, Japan). The results
were obtained at day 0 as a baseline reading. Subse-
quently, the culture medium was removed and the cells
were stimulated with or without TNF-α (10 ng/ml). Four
hours later, the cultured cells were exposed to LIPUS or
sham exposure. After 1 day of culturing, the cell numbers
were counted again. Cell proliferation was evaluated based
on the ratio of treated cells to untreated control cells.
Immunofluorescence
Cells grown on a coverslip were treated with or without
TNF-α (10 ng/ml) for 4 h, then received LIPUS or sham
exposure. Twenty-four hours later, the cells were washed
twice with phosphate-buffered saline (PBS), fixed in 4 %
paraformaldehyde in PBS for 20 min, and then incu-
bated for 1 h at 37 °C with goat antihuman AQP5 anti-
body (1:100, sc-28628; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). After three washes with PBS contain-
ing 1 % bovine serum albumin, the cells were incubated
for 1 h with Alexa Flour 488–conjugated secondary anti-
body (1:1000; Cell Signaling Technology, Danvers, MA,
USA) at room temperature (RT) in the dark. After the
unbound antibodies were washed away, coverslips were
mounted using fluorescence mounting medium (Dako,
Glostrup, Denmark). Bound antibody was observed using
a fluorescence microscope (BZ-9000; KEYENCE, Osaka,
Japan), and the fluorescence intensity was quantified by
using the BZ analyzer (KEYENCE).
Net fluid secretion rate measurements
The net fluid secretion rates for NS-SV-AC and NS-SV-
DC cells treated with or without TNF-α (10 ng/ml), as
well as those that additionally received LIPUS or sham
exposure, were measured using a modified method de-
scribed previously [28]. Briefly, 4 h after LIPUS or sham
exposure, the liquid on the apical side was collected and
its volume was measured using a calibrated pipette.
RNA isolation and real-time polymerase chain reaction
analysis
Cultured NS-SV-AC and NS-SV-DC cells were treated
with or without TNF-α (10 ng/ml) or interleukin (IL)-1β
(1 ng/ml) and received LIPUS or sham exposure. After
4 h, total cellular RNA was extracted using NucleoSpin
RNA (MACHEREY-NAGEL, Düren, Germany). First-
strand cDNA was synthesized from total RNA (1000 ng)
using a High Capacity RNA-to-cDNA Kit (Applied
Biosystems, Foster City, CA, USA). Using real-time PCR
analysis with StepOnePlus (Applied Biosystems) and
TaqMan Fast Advanced Master Mix (Applied Biosystems),
mRNA levels of AQP5, TNF-α, and A20 were examined.
The following TaqMan probe mixtures were used: TaqMan
gene expression assays; AQP5, Hs00387048_m1; TNF-α,
Hs01113624_g1; A20, Hs00234713_m1; and β-actin,
Hs01060665_g1 (Applied Biosystems). The cycling condi-
tions included 20 s at 95 °C, 40 cycles of 1 s at 95 °C, and
20 s at 60 °C. Detection of β-actin was used as an internal
control. Expression of AQP5, TNF-α, and A20 were calcu-
lated using the cycle threshold method.
Western blot analysis
Cultured in vitro NS-SV-AC and NS-SV-DC cells were
treated with or without TNF-α (10 ng/ml) or IL-1β
(1 ng/ml) and then received LIPUS or sham exposure.
After 24 h, the cells were precipitated and lysed with
M-PER Mammalian Protein Extraction Reagent (Thermo
Fisher Scientific, Waltham, MA, USA). Salivary glands
were homogenized in vivo with T-PER Mammalian Pro-
tein Extraction Reagent (Thermo Fisher Scientific). The
samples were centrifuged, and the protein concentration
of each supernatant was measured using a bicinchoninic
acid protein assay kit (Thermo Fisher Scientific) and
microplate reader (Corona Electric, Hitachinaka, Japan).
SDS-PAGE was used to separate each 20-μg sample in
vitro and each 40-μg sample in vivo, and the separated
proteins were then transferred electrophoretically onto
polyvinylidene difluoride membranes (EMD Millipore,
Billerica, MA, USA). The membranes were blocked for
1 h at RT with 0.1 % Tris-buffered saline with Tween
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20 (TBS-T) containing 3 % skim milk, then incubated
overnight at 4 °C with antihuman AQP5 antibody
(1:500; Santa Cruz Biotechnology), anti-TNF-α antibody
(1:500, catalog number 3707; Cell Signaling Technology),
phosphorylated inhibitor of nuclear factor of κ light
polypeptide gene enhancer in B cells, α subunit (phospho-
IκBα) antibody (1:1000, catalog number 9246; Cell Signal-
ing Technology), IκBα antibody (1:1000, catalog number
9242; Cell Signaling Technology), phospho-NF-κB p65
antibody (1:1000, catalog number 3033; Cell Signaling
Technology), NF-κB p65 antibody (1:1000, catalog
number 8242; Cell Signaling Technology), phosphorylated
inhibitor of nuclear factor κB kinase subunit β (phospho-
IKKβ) antibody (1:1000, catalog number 2697; Cell Signal-
ing Technology), IKKβ antibody (1:1000, catalog number
2678; Cell Signaling Technology), interleukin 1 receptor-
associated kinase 1 (IRAK1) antibody (1:1000, catalog
number 4504; Cell Signaling Technology), or anti-β-actin
antibody (1:1000, catalog number 4967; Cell Signaling
Technology) in TBS-T. The membranes were washed
three times with TBS-T for 15 min and then incubated
for 1 h with the appropriate secondary antibodies con-
jugated to horseradish peroxidase (HRP). Bound anti-
bodies were visualized using a Western blot detection
system with LumiGLO reagent (Cell Signaling Technol-
ogy) according to the manufacturer’s instructions. Pro-
tein bands were quantitated in vivo by densitometric
analysis using image analysis software (CS Analyzer;
ATTO, Tokyo, Japan).
Fluid secretion measurements
Control mice (aged 6, 12, 20, and 24 weeks old) and ex-
perimental mice (12 and 20 weeks old) had their salivary
volumes measured following LIPUS treatment. A modified
measurement method described previously was used [29].
Briefly, an intramuscular injection of pilocarpine (5 mg/
kg) was administered without anesthesia. The total vol-
ume of saliva was then determined gravimetrically after a
20-minute collection period according to a method used
in a Saxon test for the diagnosis of patients with SS [30].
Histology
After measuring fluid secretion, all salivary glands were
resected, fixed with 4 % phosphate-buffered formaldehyde
(pH 7.2), and prepared for histological examination.
Formalin-fixed tissue sections (6 μm) were then subjected
to hematoxylin and eosin staining, and three pathologists
independently evaluated the histology without being in-
formed of the condition of each mouse.
Histological grading was performed according to a previ-
ously proposed method [31]. Briefly, longitudinal sections
of all glands were examined at × 150 magnification and
scored for the degree of inflammatory infiltrate observed.
Scoring ranged from 1 to 4 and was used to indicate that
1= 1–5 foci of mononuclear cells were observed among
more than 20 cells; 2= more than 5 such foci were observed
without significant parenchymal destruction; 3= multiple
confluent loci were observed with moderate degeneration
of parenchymal tissue; and 4= extensive infiltration of the
glands with mononuclear cells and extensive parenchymal
destruction were observed, respectively.
Immunohistochemical staining of AQP5
Sections of salivary glands were deparaffinized and rehy-
drated in a xylene-ethanol series. After the endogenous per-
oxidases in each section were blocked, the sections were
incubated overnight with an antihuman AQP5 antibody
(1:200 in an antibody solution buffer; Santa Cruz Biotech-
nology) at 4 °C. After the sections were washed three times
with PBS, they were incubated with EnVision + Rabbit/HRP
(Dako) as a secondary antibody. Immunoreactivity was de-
tected using diaminobenzidine (Dako), and each section was
counterstained with Mayer’s hematoxylin.
Statistical analysis
Mean and standard deviation values were calculated. Sig-
nificant differences in experimental data were analyzed by
one-way analysis of variance, followed by the Tukey–
Kramer test and the Bonferroni–Dunn test as a post
hoc test to examine mean differences at the 5 % level of
significance.
Results
Effects of LIPUS on cell proliferation
Compared with untreated control cells, cells stimulated
with TNF-α showed a significant decrease in the number
and proliferation of adherent NS-SV-AC and NS-SV-DC
cells that were detected (p < 0.01) (Fig. 1a, b). In con-
trast, the subsequent LIPUS treatment induced a signifi-
cant increase in proliferation for both NS-SV-AC and
NS-SV-DC cells stimulated with TNF-α (p < 0.01). Treat-
ment with LIPUS alone had no catabolic effect on cell
proliferation.
AQP5 expression in NS-SV-AC and NS-SV-DC cells
Untreated NS-SV-AC cells exhibited intense AQP5
expression compared with untreated NS-SV-DC cells
(Fig. 1c, Additional file 2: Figure S2). However, following
treatment with TNF-α, AQP5 expression markedly de-
creased, especially in the NS-SV-AC cells. When NS-SV-
AC and NS-SV-DC cells were treated with TNF-α and
then LIPUS, AQP5 levels increased to match the baseline
level of AQP5 expression exhibited by untreated cells. In
contrast, LIPUS treatment alone had no effect on AQP5
expression.
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Fluid secretion rate in NS-SV-AC and NS-SV-DC cells
Compared with the secretion rate of untreated control
cells, stimulation with TNF-α resulted in a significant
decrease in the net fluid secretion rate of NS-SV-AC
and NS-SV-DC cells (p < 0.01) (Fig. 1d). However, when
LIPUS treatment was administered following TNF-α
treatment, significant increases in the net fluid secretion
rate of both cells were observed (p < 0.05).
Gene and protein expression of AQP5 and TNF-α in
NS-SV-AC and NS-SV-DC cells treated with TNF-α
Compared with control cells, the stimulation of both NS-
SV-AC and NS-SV-DC cells with TNF-α resulted in a sig-
nificant decrease in levels of AQP5 mRNA (p < 0.01) and a
significant increase in levels of TNF-α mRNA (p < 0.01)
(Fig. 2a, b). However, the latter was reversed following
treatment with LIPUS (NS-SV-AC, p < 0.05; NS-SV-DC,
p < 0.01). Moreover, LIPUS treatment of untreated NS-
SV-AC cells resulted in a significant increase in levels of
AQP5 mRNA (Fig. 2a, b).
The intensity of the AQP5 band detected was decreased
following TNF-α stimulation, whereas expression of TNF-α
was clearly enhanced (Fig. 2c, Additional file 3: Figure S3).
However, when LIPUS treatment was performed after
TNF-α treatment, an increase in AQP5 levels was observed
in both NS-SV-AC and NS-SV-DC cell extracts compared
with untreated control cells. In contrast, AQP5 levels of un-
treated cells that received LIPUS treatment alone exhibited
minimal, if any, change in signal intensity.
Mechanism of LIPUS on NS-SV-AC and NS-SV-DC cellular
function
To determine whether LIPUS inhibits inflammation in
NS-SV-AC and NS-SV-DC cells through the prevention
of NF-κB activation, we investigated the effect of IκBα,
NF-κB, and IKKβ phosphorylation inhibition on phosphor-
ylation of proteins involved in anti-inflammatory effects.
Western blot analysis showed IκBα, NF-κB, and IKKβ
phosphorylation were obviously induced by TNF-α
stimulation; however, LIPUS exposure following TNF-α
treatment inhibited IκBα, NF-κB, and IKKβ phosphorylation
Fig. 1 Effects of LIPUS on NS-SV-AC and NS-SV-DC cells. a Following TNF-α stimulation, a significant decrease in cell numbers was observed for both
cell types. These numbers increased following a single exposure to LIPUS. These data are presented as the fold number relative to each control cell
type. *p < 0.05; **p < 0.01 (n = 6). b 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt assay showed
results similar to the cell count assay for both cell types. *p < 0.05; **p < 0.01 (n = 5). c Immunofluorescence assays were performed to detect expression
of AQP5 (green) in NS-SV-AC and NS-SV-DC cells. Staining intensity markedly decreased following TNF-α treatment, whereas TNF-α plus LIPUS restored
AQP5 expression to levels exhibited by untreated cells. Scale bar = 100 μm. d The net water flow (e.g., fluid secretion rates) for NS-SV-AC and NS-SV-DC
cells were significantly lower following TNF-α stimulation, whereas TNF-α plus LIPUS significantly increased the rate for both cell types. *p < 0.05;
**p < 0.01 (n = 3). AQP5 aquaporin 5, LIPUS low-intensity pulsed ultrasound, NS-SV-AC salivary gland acinar cells, NS-SV-DC salivary gland ductal cells,
TNF-α tumor necrosis factor α
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in both NS-SV-AC and NS-SV-DC cells (Fig. 3a, Additional
file 4: Figure S4A). In addition, IκBα, NF-κB, and IKKβ
phosphorylation induced by IL-1β stimulation was also
inhibited by LIPUS exposure (Fig. 3b, Additional file 4:
Figure S4B). This indicates that anti-inflammatory effects of
LIPUS are not a specific response to TNF-α stimulation.
Furthermore, to determine LIPUS effects on the up-
stream of NF-κB signaling pathway, we examined IRAK1
expression on IL-1β stimulation. IRAK1 was degraded by
IL-1β stimulation, and LIPUS exposure failed to inhibit
the degradation of IRAK1 induced by IL-1β stimulation
(Fig. 3c, Additional file 4: Figure S4C). This means that
Fig. 2 Gene and protein expression of TNF-α and AQP5 in NS-SV-AC and NS-SV-DC cells. TNF-α stimulation of NS-SV-AC and NS-SV-DC cells significantly
increased levels of TNF-α mRNA (a) and decreased levels of AQP5 mRNA. (b). Detection of β-actin mRNA was used to calculate relative fold induction for
each. However, when TNF-α stimulation was followed by LIPUS, both levels were restored to those of control cells. *p< 0.05; **p< 0.01 (n = 6). c In Western
blot assays, the expression of the AQP5 was decreased following TNF-α stimulation, whereas the expression of TNF-α was increased, in both cell types.
When LIPUS was performed following TNF-α treatment, levels of AQP5 were increased in both cell types compared with untreated controls. AQP5
aquaporin 5, LIPUS low-intensity pulsed ultrasound, NS-SV-AC salivary gland acinar cells, NS-SV-DC salivary gland ductal cells, TNF-α tumor necrosis factor α
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Fig. 3 (See legend on next page.)
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the effect point of LIPUS on the NF-κB signaling pathway
is downstream of IRAK1. Next, we examined A20 (tumor
necrosis factor-α-induced protein 3 [TNFAIP3]) mRNA
expression using real-time PCR. A20 is known as the
intracellular ubiquitin-editing protein and a key player in
the negative feedback of NF-κB signaling in response to
multiple stimulation [32]. Compared with untreated
control cells, the stimulation of both NS-SV-AC and
NS-SV-DC cells with TNF-α or IL-1β resulted in a
significant increase in levels of A20 mRNA (p < 0.01).
Furthermore, A20 mRNA expression was more in-
creased by treatment with LIPUS after TNF-α or IL-1β
stimulation (NS-SV-AC, p < 0.01; NS-SV-DC, p < 0.05)
(Fig. 3d). These data show that LIPUS activates A20,
which produces negative feedback of NF-κB signaling
in response to inflammatory stimulation, resulting in
inhibition of inflammation in salivary gland cells.
Changes in fluid secretion volumes with aging
The average salivary volumes for 12-week-old, 20-
week-old, and 24-week-old MRL/lpr mice were signifi-
cantly lower than those obtained from 6-week-old mice
(p < 0.01) (Fig. 4a). Moreover, compared with C57BL/6
mice, the average salivary secretion volumes for the
MRL/lprmice were significantly lower at all ages (p < 0.01).
In vivo effect of LIPUS on salivary secretion in MRL/lpr mice
To examine the effect of LIPUS on salivary secretion in
MRL/lpr mice, secreted saliva volumes were measured
using a modified method employed in the Saxon test
[21]. Following LIPUS treatment, salivary secretion was
found to be restored in both 12-week-old and 20-week-
old MRL/lpr mice to a degree comparable to that of
younger C57BL/6 mice (Fig. 4b). Furthermore, both 12-
week-old and 20-week-old MRL/lpr mice exhibited a
significant increase in salivary secretion following LIPUS
treatment compared with untreated MRL/lpr mice.
Anti-inflammatory effect of LIPUS on salivary glands in
MRL/lpr mice
MRL/lpr mice treated with LIPUS showed a marked re-
duction in histological damage, such as the lymphocyte
infiltration of surrounding duct and the destruction of
gland tissue, compared with untreated MRL/lpr mice
(Additional file 5: Figure S5A). Moreover, the histo-
logical score for the inflammatory lesions of the sub-
mandibular glands of MRL/lpr mice was significantly
improved following LIPUS (p < 0.05) (Fig. 4c).
AQP5 expression in salivary glands
As shown in Fig. 4d, submandibular gland acinar cells of
untreated MRL/lpr mice showed weak staining for AQP5
expression (brown stain) in both the serous and mucous
acini of the submandibular glands. In contrast, strong
expression of AQP5 was observed at apical sites in sub-
mandibular gland acinar cells of MRL/lpr mice treated
with LIPUS.
Induction of AQP5 and TNF-α expression in salivary
glands
Following LIPUS exposure, significantly lower levels of
TNF-α (p < 0.05) and significantly higher levels of AQP5
(p < 0.05) were detected in the salivary glands of treated
MRL/lpr mice compared with untreated MRL/lpr mice
(Fig. 4e, Additional file 5: Figure S5B).
Discussion
To our knowledge, the effect of LIPUS on salivary gland
cells has not previously been investigated. Thus, the
present study would be the first to investigate the effect
of LIPUS on cell proliferation and the synthesis of AQP5
in normal human salivary gland acinar and ductal cells
stimulated with TNF-α. The present results indicate that
LIPUS is able to upregulate cell proliferation and AQP5
expression in both of these stimulated cell types. Fur-
thermore, using a mouse model of autoimmune sialade-
nitis in SS, LIPUS treatment was found to improve
secretion from salivary glands in both age-related and SS
xerostomia experiments.
Although the mechanisms mediating LIPUS-stimulated
tissue repair have not yet been elucidated, it is hypothe-
sized that the anabolic biophysical effects of ultrasound
are due to mechanical stress and/or the impact of fluid
microstreaming on the cellular plasma membrane, focal
adhesions, and cytoskeletal structures. As a result, intra-
cellular signal transduction is activated and gene tran-
scription is affected [33]. There is evidence to suggest that
LIPUS activates integrins on the cell surface that act as
(See figure on previous page.)
Fig. 3 Anti-inflammatory mechanism of LIPUS on NS-SV-AC and NS-SV-DC cellular function. a Western blot analysis showed IκBα phosphorylation
was obviously induced by TNF-α stimulation; however, when LIPUS treatment was administered following TNF-α treatment, IκBα, NF-κB, and IKKβ
phosphorylation were inhibited. b Similar inhibitory effects of LIPUS were observed in IL-1β stimulation. c In Western blot analysis, IRAK1 was
degraded after IL-1β stimulation, and LIPUS exposure failed to inhibit it. d The stimulation of both NS-SV-AC and NS-SV-DC cells with TNF-α or
IL-1β resulted in a significant increase in levels of A20 mRNA, and A20 mRNA expression was further increased following treatment with LIPUS
after TNF-α or IL-1β stimulation. *p < 0.05; **p < 0.01 (n = 6). A20 tumor necrosis factor-α-induced protein 3 (TNFAIP3), IKKβ inhibitor of nuclear
factor κB kinase subunit β, IL-1β interleukin 1β, IRAK1 interleukin 1 receptor-associated kinase 1, IκBα inhibitor of nuclear factor of κ light
polypeptide gene enhancer in B cells, α subunit, LIPUS low-intensity pulsed ultrasound, NF-κB nuclear factor κB, NS-SV-AC salivary gland acinar
cells, NS-SV-DC salivary gland ductal cells, TNF-α tumor necrosis factor α
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mechanoreceptors to promote the attachment of various
focal adhesion adaptor proteins [34]. In addition, levels of
phosphorylated focal adhesion kinase (FAK) in synovial
cells were found to increase following LIPUS treatment
[35, 36]. Furthermore, LIPUS treatment of cementoblasts
has been shown to enhance expression of extracellular
signal-regulated kinase 1/2 [35]. Because the proliferation
of various cell types is mediated by growth factors
or cytokine-induced mitogen-activated protein kinase
(MAPK) proteins [37], the exposure of salivary gland
cells to LIPUS may lead to specific activation of an
integrin/FAK/MAPK pathway.
In human salivary glands, AQP5 localizes to the apical
membranes of acinar cells and stimulates the outflow of
water into the acinar lumen [38]. In patients with SS,
the salivary and lacrimal glands exhibit a marked reduc-
tion in AQP expression in the plasma membrane [39],
as well as a delocalization of AQP5 to the basal mem-
brane [40]. Correspondingly, reduced salivary gland se-
cretion has been observed in mice harboring a mutant
AQP5 channel [41]. Therefore, although the molecular
mechanisms by which AQP5 dysfunction is induced in
the salivary and lacrimal glands of patients with SS remains
unknown, it appears that enhancement of AQP5 expres-
sion in salivary acinar cells may be a critical aspect. In the
present study, expression of AQP5 in NS-SV-AC and
NS-SV-DC cells was inhibited by TNF-α treatment, whereas
it was recovered following LIPUS exposure. Furthermore,
AQP5 synthesis and expression in the salivary glands of
MRL/lpr mice was restored following LIPUS treatment,
resulting in the restoration of salivary flow to normal levels.
In this study, we hypothesize that this event is due to
the anti-inflammatory effects mediated by LIPUS treat-
ment through the prevention of NF-κB activation. NF-
κB is composed of homo- and heterodimeric complexes
of members of the Rel protein family. NF-κB normally
resides in the cytoplasm, where it is retained by associ-
ation with IκB protein, an endogenous inhibitor. Various
extracellular stimuli trigger the degradation of IκB by
the proteasome pathway. Subsequently, NF-κB released
from IκB translocates into the nucleus, binds to the
regulatory element of the target genes, and controls their
Fig. 4 In vivo effects of LIPUS on MRL/lpr mice. a The average salivary volumes of 12-week-old, 20-week-old, and 24-week-old MRL/lpr mice were
lower those of 6-week-old MRL/lpr mice. The average salivary secretion of the MRL/lpr mice at each age was also significantly lower than that for
C57BL/6 mice at the same ages. **p< 0.01; ‡p< 0.01 compared with 6-week-old C57BL/6 mice; ##p< 0.01 compared with 6-week-old MRL/lpr mice (n = 5).
b Both 12-week-old and 20-week-old MRL/lpr mice showed a significant increase in salivary flow following LIPUS treatment. **p< 0.01 (n = 5). c Histological
scores for inflammatory lesions present in the salivary glands of untreated versus LIPUS-treated MRL/lpr mice. LIPUS treatment significantly improved the
histological score. *p< 0.05 (n = 5). d In both the serous and mucous acini of the submandibular glands, acinar cells of untreated MRL/lpr mice exhibited
weak staining for AQP5, whereas intense staining of AQP5 was localized to apical sites in acinar cells of MRL/lpr mice treated with LIPUS (arrows).
Scale bar = 100 μm. e In Western blot assays, levels of TNF-α were significantly lower, and levels of AQP5 were significantly higher, following LIPUS
treatment compared with untreated MRL/lpr samples. Detection of β-actin was used to calculate relative fold induction for each. *p < 0.05 (n = 5).
AQP5 aquaporin 5, LIPUS low-intensity pulsed ultrasound, MRL/lpr MRL/MpJ/lpr/lpr, TNF-α tumor necrosis factor α
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transcription [42]. Our results demonstrated that the
anti-inflammatory effects of LIPUS in NS-SV-AC and
NS-SV-DC cells were involved in the inhibition of NF-
κB signaling pathway. Interestingly, LIPUS activated the
intracellular ubiquitin-editing protein A20 in inflamma-
tory stimulation. A20, a cytoplasmic zinc finger protein,
was originally identified as a TNF-inducible protein. It
has been characterized as a dual inhibitor of NF-κB
activation and cell death [31] and functions as a negative
feedback regulator of NF-κB activation via multiple
mechanisms [43]. Furthermore, A20 inhibits TNF- and
IL-1-induced NF-κB activation in 293 cells [44], and
deregulated Toll-like receptor signaling in response to
commensal bacteria was shown to be responsible for the
multiorgan inflammation and premature death of A20-
knockout mice [45]. Thus, LIPUS may inhibit the NF-κB
pathway by activating a negative feedback system in the
salivary gland acinar and ductal cells.
In IL-1β-stimulated synovial membrane cells, increased
expression of cyclooxygenase 2 (Cox-2), a NF-κB-
responsible gene, was found to be significantly inhib-
ited by LIPUS in vitro [24]. Expression of Cox-2 in the
knee joints of MRL/lpr mice was also found to be mark-
edly reduced following daily treatments with LIPUS [25],
whereas inhibition of Cox-2 was found to reduce the
proliferation and induce the apoptosis of human chol-
angiocarcinoma QBC939 cells via inhibition of prosta-
glandin E2 production [46]. On the basis of these data,
it is hypothesized that inhibition of Cox-2 expression by
LIPUS restores salivary secretion in MRL/lpr mice as a
secondary effect.
It is generally accepted that salivary secretion volume
decreases with age. The prevalence of xerostomia also
increases with age and affects approximately 30 % of
people aged 65 years or older [47]. In contrast, the pro-
duction and composition of saliva remains largely inde-
pendent of age in healthy individuals [48, 49]. Recently,
Yamamura et al. [50] postulated that age-related hyper-
methylation of the AQP5 gene could account for the
downregulation of AQP5 expression that is observed in
the salivary glands of patients with SS. Correspondingly,
demethylation of the AQP5 promoter in salivary gland
cells by 5-aza-2′-deoxycytidine (decitabine) could poten-
tially restore salivary flow in aged mice. The results of
the present study demonstrate that the average salivary
volumes of the 12-week-old and older MRL/lpr and
wild-type mice were significantly lower than those of the
6-week-old mice. In addition, LIPUS treatment restored
the salivary secretion volume of both the 12-week-old
and 20-week-old MRL/lpr mice to the salivary flow level
observed in the younger wild-type mice. Thus, it appears
that reduced salivary flow in older MRL/lpr mice is a
consequence of autoimmune disease as well as the aging
process, and LIPUS treatment can compensate for these
processes. However, further studies are needed to iden-
tify the effect of LIPUS on age-related xerostomia to
understand how LIPUS affects salivary glands and their
cells.
In recent years, LIPUS has been paid attention as a
physical therapy that has insignificant side effects. In this
study, we investigated the effectiveness of LIPUS on xer-
ostomia associated with SS, and the results suggest that
LIPUS might rescue salivary secretion volume in an SS
mouse model by their anti-inflammatory effect in the
salivary gland tissue. Furthermore, LIPUS has much po-
tential for clinical application because it can be used in
combination with conventional pharmacotherapy. Our re-
sults also suggest that further studies to determine clinical
efficacy, safety, and response duration are warranted.
Conclusions
LIPUS treatment was found to increase cell proliferation
and AQP5 expression in salivary gland cells pretreated with
TNF-α in vitro. Moreover, LIPUS activates the intracellular
ubiquitin-editing protein A20, which produces negative
feedback of NF-κB signaling in response to inflammatory
stimulation. LIPUS exposure also restored salivary gland
secretion volumes in older MRL/lpr mice in vivo, thereby
promoting an anti-inflammatory response and improving
AQP5 dysfunction. Therefore, LIPUS stimulation may rep-
resent a treatment strategy for inflammatory diseases of
salivary glands, including xerostomia in SS.
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